• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Study Finds Digital Asthma Program Significantly Improves Symptom Control in Adults

    7/22/25 9:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care
    Get the next $ELV alert in real time by email

    Elevance Health and UC Irvine study underscores potential of digital health tools to reduce asthma burden across U.S. populations

    A groundbreaking clinical trial led by multidisciplinary researchers found that a digital asthma self-management (DASM) program significantly improved asthma symptom control in adults, with benefits sustained over 12 months. Program participants used everyday devices - like Apple Watch and iPhone – along with a tailored mobile app to help them manage their asthma. The findings represent some of the most compelling evidence to date supporting the use of digital health technologies in asthma care.

    The virtual, randomized, controlled and decentralized study was conducted by Elevance Health and University of California, Irvine, in collaboration with Apple, Inc. The trial enrolled 901 adult participants across 41 U.S. states, including individuals with commercial and Medicaid coverage. The DASM group used an iPhone app integrated with Apple Watch to track asthma-related metrics, receive personalized alerts, and log symptoms—demonstrating the scalability and potential of DASM to support asthma self-management nationwide.

    Among participants with uncontrolled asthma at baseline, those receiving DASM improved Asthma Control Test (ACT) scores by an average of 4.6 points over 12 months—compared to 1.8 points in the control group. This can mean improvements such as less shortness of breath or asthma-related disruption of day-to-day activities. Among individuals with controlled asthma at baseline, results also favored DASM over the control group (usual care), though less robustly.

    Notably, the study found consistent benefit across insurance types and ethnicities, though effects were decreased among African American participants. Engagement metrics—such as symptom log activity and app usage—correlated with improved outcomes.

    "These results support continued development of digital asthma self-management programs," said Jordan Silberman, MD, PhD, co-lead author and Director of Clinical Analytics at Elevance Health. "Findings also underscore the need for culturally adaptive strategies to ensure equitable engagement and impact across all communities affected by asthma."

    Secondary outcomes revealed additional benefits for DASM users, including improved medication adherence, greater confidence in self-management, and reduced impact of asthma on work productivity.

    "We are proud to support research that not only improves chronic disease management but prioritizes underserved populations often left behind in digital innovation," said Richard A. Lee, MD, co-author and Associate Clinical Professor, Pulmonary and Critical Care Medicine at UC Irvine.

    View the full article via JAMA Network Open: A Digital Asthma Self-Management Program for Adults: A Randomized Clinical Trial.

    About Elevance Health

    Elevance Health is a lifetime, trusted health partner whose purpose is to improve the health of humanity. The company supports consumers, families, and communities across the entire healthcare journey – connecting them to the care, support, and resources they need to lead better lives. Elevance Health's companies serve over 109 million consumers through a diverse portfolio of industry-leading medical, pharmacy, behavioral, clinical, home health, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on X and Elevance Health on LinkedIn.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250722917743/en/

    Media Contact:

    Lindsay Wehr

    Director, Corporate Media Relations

    Elevance Health

    [email protected]

    Get the next $ELV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELV

    DatePrice TargetRatingAnalyst
    10/14/2025Neutral
    Goldman
    7/21/2025Buy → Hold
    Argus
    7/18/2025$310.00Outperform → Market Perform
    Leerink Partners
    4/15/2025$529.00Outperform → Neutral
    Robert W. Baird
    3/17/2025$450.00Hold → Buy
    Argus
    1/22/2025$520.00 → $440.00Overweight → Equal-Weight
    Stephens
    10/18/2024Buy → Hold
    Argus
    7/18/2024$646.00 → $530.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $ELV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: New insider Craig Ryan R claimed ownership of 3,341 shares (SEC Form 3)

    3/A - Elevance Health, Inc. (0001156039) (Issuer)

    11/21/25 4:17:27 PM ET
    $ELV
    Medical Specialities
    Health Care

    EVP & CFO Kaye Mark covered exercise/tax liability with 2,895 shares, decreasing direct ownership by 15% to 16,082 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    10/3/25 4:17:15 PM ET
    $ELV
    Medical Specialities
    Health Care

    EVP & Chief Legal Officer Wessling Erin M covered exercise/tax liability with 152 shares, decreasing direct ownership by 3% to 5,020 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    9/5/25 4:21:42 PM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Elevance Health

    Goldman initiated coverage of Elevance Health with a rating of Neutral

    10/14/25 8:49:08 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health downgraded by Argus

    Argus downgraded Elevance Health from Buy to Hold

    7/21/25 8:26:59 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Elevance Health from Outperform to Market Perform and set a new price target of $310.00

    7/18/25 8:10:27 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    SEC Filings

    View All

    Elevance Health Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Elevance Health, Inc. (0001156039) (Filer)

    12/10/25 4:35:16 PM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Elevance Health, Inc. (0001156039) (Filer)

    11/10/25 5:03:08 PM ET
    $ELV
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by Elevance Health Inc.

    10-Q - Elevance Health, Inc. (0001156039) (Filer)

    10/21/25 11:11:08 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Devore Susan D. bought $374,580 worth of shares (1,200 units at $312.15), increasing direct ownership by 52% to 3,502 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    8/21/25 4:20:38 PM ET
    $ELV
    Medical Specialities
    Health Care

    President and CEO Boudreaux Gail bought $2,438,951 worth of shares (8,500 units at $286.94), increasing direct ownership by 6% to 151,020 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    7/18/25 1:42:51 PM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Elevance Health Reflects On The Changed Role of Health Plans

    By simplifying the healthcare experience, improving care coordination, and leveraging data-driven insights, Elevance Health affiliated health plans help members navigate a range of healthcare experiences with greater confidence As 2025 draws to a close, Elevance Health highlights how today's health plans are evolving to better support their members in a broader range of situations that affect health, including cancer diagnoses, mental health crises, and unexpected health concerns during pregnancy. From employer-sponsored health insurance to government-sponsored programs, health plans are evolving to better support their members in a broader range of situations that affect health. In partne

    12/12/25 2:00:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    AM Best Takes Various Credit Rating Actions on Elevance Health, Inc. and Most of Its Subsidiaries

    AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of "a+" (Excellent) of the core Blue Cross Blue Shield (BCBS)-branded insurance subsidiaries of Elevance Health, Inc. (Elevance) (Indianapolis, IN) (NYSE:ELV), as well as most of its non-Blue-branded subsidiaries. In addition, AM Best has upgraded the FSR to A (Excellent) from A- (Excellent) and the Long-Term ICR to "a+" (Excellent) from "a-" (Excellent) of Wellpoint Life and Health Insurance Company and Wellpoint West Virginia, Inc. These companies collectively are referred to as Anthem Health. At the same time, AM Best has affirmed the Long-Term ICR of "bbb+"

    12/12/25 11:10:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Board Welcomes Amy Schulman as New Director, Reflecting Ongoing Commitment to Governance Excellence

    The board of directors of Elevance Health (NYSE:ELV) today announced the appointment of Amy Schulman, a recognized healthcare executive, investor, and governance leader, as an independent director, effective January 12, 2026. Schulman will serve on the Audit and Finance Committees, contributing deep expertise in healthcare innovation, regulatory strategy, and value creation across complex, global enterprises. This appointment reflects Elevance Health's ongoing board refreshment strategy to ensure diverse, independent, and future-focused leadership that aligns with the company's long-term strategy and stakeholders' priorities. "Amy's record of driving innovation, disciplined investment, an

    12/10/25 4:30:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Financials

    Live finance-specific insights

    View All

    AM Best Takes Various Credit Rating Actions on Elevance Health, Inc. and Most of Its Subsidiaries

    AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of "a+" (Excellent) of the core Blue Cross Blue Shield (BCBS)-branded insurance subsidiaries of Elevance Health, Inc. (Elevance) (Indianapolis, IN) (NYSE:ELV), as well as most of its non-Blue-branded subsidiaries. In addition, AM Best has upgraded the FSR to A (Excellent) from A- (Excellent) and the Long-Term ICR to "a+" (Excellent) from "a-" (Excellent) of Wellpoint Life and Health Insurance Company and Wellpoint West Virginia, Inc. These companies collectively are referred to as Anthem Health. At the same time, AM Best has affirmed the Long-Term ICR of "bbb+"

    12/12/25 11:10:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Reports Third Quarter 2025 Results

    Executing with discipline to improve affordability and elevate the member experience 3Q 2025 operating revenue of $50.1 billion, up 12.0% from 3Q 2024 3Q 2025 diluted EPS1 of $5.32; adjusted diluted EPS2 of $6.03 Reaffirm FY 2025 benefit expense ratio and adjusted diluted EPS guidance of approximately 90.0% and approximately $30.00, respectively Returned $3.3 billion of capital to shareholders year-to-date Elevance Health, Inc. (NYSE:ELV) reported third quarter 2025 results. "Our third quarter results were in line with expectations and reflect disciplined execution across Elevance Health. In a dynamic healthcare environment, we're focused on advancing affordability and ele

    10/21/25 6:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health to Hold Conference Call and Webcast to Discuss Third Quarter 2025 Results on October 21

    Elevance Health (NYSE: ELV) will release third quarter 2025 financial results on October 21, 2025, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 - Access Code - 3972058 (Domestic) 312-470-0178 - Access Code - 3972058 (International) 800-391-9853 - No Access Code (Domestic Replay) 203-369-3269 - No Access Code (International Replay) The replay will be available from 11:30 a.m. EDT on October 21, 2025, until the end of the day on November 21, 2025. Th

    9/29/25 4:30:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Elevance Health Inc.

    SC 13G/A - Elevance Health, Inc. (0001156039) (Subject)

    11/14/24 1:22:35 PM ET
    $ELV
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Elevance Health Inc.

    SC 13G - Elevance Health, Inc. (0001156039) (Subject)

    2/14/24 10:02:59 AM ET
    $ELV
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Elevance Health Inc.

    SC 13G - Elevance Health, Inc. (0001156039) (Subject)

    2/14/23 12:37:59 PM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Leadership Updates

    Live Leadership Updates

    View All

    Elevance Health Board Welcomes Amy Schulman as New Director, Reflecting Ongoing Commitment to Governance Excellence

    The board of directors of Elevance Health (NYSE:ELV) today announced the appointment of Amy Schulman, a recognized healthcare executive, investor, and governance leader, as an independent director, effective January 12, 2026. Schulman will serve on the Audit and Finance Committees, contributing deep expertise in healthcare innovation, regulatory strategy, and value creation across complex, global enterprises. This appointment reflects Elevance Health's ongoing board refreshment strategy to ensure diverse, independent, and future-focused leadership that aligns with the company's long-term strategy and stakeholders' priorities. "Amy's record of driving innovation, disciplined investment, an

    12/10/25 4:30:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Appoints Nathan Rich Vice President, Investor Relations

    Elevance Health (NYSE:ELV) announced today the appointment of Nathan Rich as Vice President, Investor Relations, effective November 11, 2024. In this role, Mr. Rich will lead Elevance Health's investor relations efforts, providing strategic leadership to support the company's growth initiatives and strengthen relationships within the investment community. He will also serve as a member of the company's executive leadership team and will report directly to Mark Kaye, Executive Vice President and Chief Financial Officer. Mr. Rich succeeds Stephen Tanal, who now serves as Chief Financial Officer for Elevance Health's Government Health Benefits business. "Nate brings nearly two decades of expe

    11/4/24 9:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    Former Deputy Commissioner of New York State Department of Health Joins Sheppard Mullin

    Nationally Recognized Healthcare Policy Leader Adam Herbst Strengthens the Firm's Regulatory Capabilities for Clients Across the Post-Acute, Aging and Long-Term Care Sectors Sheppard, Mullin, Richter & Hampton LLP is pleased to announce that Adam S. Herbst has joined the firm as a healthcare partner in New York. Most recently, Herbst served as the New York State Department of Health's Deputy Commissioner for Aging and Long Term Care. He is the ninth healthcare partner to join the firm in 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241030758975/en/Adam Herbst (Photo: Business Wire) In joining Sheppard Mullin's industry-l

    10/30/24 12:55:00 PM ET
    $ELV
    Medical Specialities
    Health Care